ATE403647T1 - Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden - Google Patents

Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden

Info

Publication number
ATE403647T1
ATE403647T1 AT01998144T AT01998144T ATE403647T1 AT E403647 T1 ATE403647 T1 AT E403647T1 AT 01998144 T AT01998144 T AT 01998144T AT 01998144 T AT01998144 T AT 01998144T AT E403647 T1 ATE403647 T1 AT E403647T1
Authority
AT
Austria
Prior art keywords
receptor ligands
indoline derivatives
indoline
derivatives
ligands
Prior art date
Application number
AT01998144T
Other languages
English (en)
Inventor
Jonathan Mark Bentley
James Edward Paul Davidson
Howard Langham Mansell
Nathaniel Julius Thomas Monck
Original Assignee
Hoffmann La Roche
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE403647T1 publication Critical patent/ATE403647T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT01998144T 2000-10-16 2001-10-12 Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden ATE403647T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00122539 2000-10-16

Publications (1)

Publication Number Publication Date
ATE403647T1 true ATE403647T1 (de) 2008-08-15

Family

ID=8170101

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998144T ATE403647T1 (de) 2000-10-16 2001-10-12 Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden

Country Status (15)

Country Link
US (1) US6479534B1 (de)
EP (1) EP1328515B1 (de)
JP (1) JP4047723B2 (de)
KR (1) KR100545435B1 (de)
CN (1) CN100334076C (de)
AR (1) AR038762A1 (de)
AT (1) ATE403647T1 (de)
AU (2) AU2002221670B2 (de)
BR (1) BR0114708A (de)
CA (1) CA2422698C (de)
DE (1) DE60135239D1 (de)
ES (1) ES2311563T3 (de)
MX (1) MXPA03003246A (de)
WO (1) WO2002044152A1 (de)
ZA (1) ZA200302516B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000830A1 (en) 2002-06-19 2003-12-31 Biovitrum Ab Novel compounds, their use and preparation
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7081696B2 (en) 2004-08-12 2006-07-25 Exro Technologies Inc. Polyphasic multi-coil generator
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
EP2286837A3 (de) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Behandlung von Fettleibigkeit und von verwandten Krankheiten
CA2597616A1 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
EP1916239A4 (de) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Pyridolverbindung
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP2330125A3 (de) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybridpolypeptide mit auswählbaren Eigenschaften
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
BRPI0617621A2 (pt) 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
EP2727585A1 (de) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo Screening-Methode
CN101501963B (zh) 2006-06-08 2012-06-13 Exro技术公司 多相多线圈发电机
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008039087A2 (en) * 2006-09-29 2008-04-03 Auckland Uniservices Limited Indoline derivatives and uses thereof
TW200823187A (en) * 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
AU2008206328B2 (en) 2007-01-16 2013-10-31 Ipintl, Llc Novel composition for treating metabolic syndrome
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2789338A3 (de) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Kondensiertes Pyridinderivat und seine Verwendung
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
EP2379562A1 (de) 2008-12-16 2011-10-26 Schering Corporation Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2510949A4 (de) 2009-12-11 2013-11-13 Astellas Pharma Inc Therapeutikum für fibromyalgie
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (de) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Neue cyclische azabenzimidazolderivate als antidiabetika
KR102034748B1 (ko) 2011-03-01 2019-10-21 시너지 파마슈티컬즈 인코포레이티드 구아닐레이트 사이클라제 c 작용제의 제조 방법
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (de) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
JP2020521418A (ja) 2017-05-23 2020-07-16 ディーピーエム テクノロジーズ インク． 可変コイル結線システム
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
US20210249981A1 (en) 2018-09-05 2021-08-12 Dpm Technologies Inc. Systems and methods for intelligent control of rotating electric machines
EP3883930A1 (de) 2018-11-20 2021-09-29 Tes Pharma S.r.l. Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase
EP3924058B1 (de) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl-pyrrolidinorexinrezeptor-agonisten
EP3923933A4 (de) 2019-02-13 2022-08-17 Merck Sharp & Dohme Corp. Pyrrolidinorexin-rezeptor-agonisten
WO2020215154A1 (en) 2019-04-23 2020-10-29 Dpm Technologies Inc. Fault tolerant rotating electric machine
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US12084419B2 (en) 2020-06-27 2024-09-10 Crescenta Biosciences Cell metabolism modulating compounds and uses thereof
US11680060B2 (en) 2020-08-18 2023-06-20 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
US11897362B2 (en) 2021-05-04 2024-02-13 Exro Technologies Inc. Systems and methods for individual control of a plurality of controllable units of battery cells
JP2024518405A (ja) 2021-05-13 2024-05-01 エクスロ テクノロジーズ インク． 多相電気機械のコイルを駆動する方法及び装置
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2541211A (en) 1948-10-15 1951-02-13 Searle & Co Tertiary-aminoalkyl-tetrahydrocarbazoles
US2687414A (en) 1948-11-26 1954-08-24 Searle & Co Method for producing aromatic aminoalkyl amines
DE930988C (de) 1953-01-01 1955-07-28 Bayer Ag Verfahren zur Herstellung von basisch alkylierten Tetrahydrocarbazolen oder Indolen
US3142678A (en) 1962-01-09 1964-07-28 American Home Prod Amino substituted penthienoindoles
US3663567A (en) * 1970-12-04 1972-05-16 Sandoz Ag N-substituted cycloalkanoindoles
GB1418703A (en) * 1973-06-02 1975-12-24 Pfizer Ltd 3-alkyl-9-substituted-1,2,3,4-tetrahydrocarbazoles
GB1432649A (de) 1973-09-07 1976-04-22 Ici Ltd
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
TW270114B (de) * 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
WO1998030548A1 (en) 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
AU759388B2 (en) 1998-08-14 2003-04-10 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors and chitosan
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii

Also Published As

Publication number Publication date
EP1328515A1 (de) 2003-07-23
MXPA03003246A (es) 2003-06-06
AU2167002A (en) 2002-06-11
EP1328515B1 (de) 2008-08-06
BR0114708A (pt) 2003-07-01
JP2004527467A (ja) 2004-09-09
WO2002044152A1 (en) 2002-06-06
AR038762A1 (es) 2005-01-26
CN100334076C (zh) 2007-08-29
KR100545435B1 (ko) 2006-01-24
US20020183349A1 (en) 2002-12-05
CN1630636A (zh) 2005-06-22
ES2311563T3 (es) 2009-02-16
US6479534B1 (en) 2002-11-12
CA2422698C (en) 2009-12-15
ZA200302516B (en) 2004-06-30
CA2422698A1 (en) 2002-06-06
DE60135239D1 (de) 2008-09-18
JP4047723B2 (ja) 2008-02-13
AU2002221670B2 (en) 2006-11-02
KR20030048437A (ko) 2003-06-19

Similar Documents

Publication Publication Date Title
ATE403647T1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60001840D1 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
ATE369368T1 (de) Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE280757T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE514676T1 (de) Ionisierbare indolinon derivate und deren verwendung als ptk liganden
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE301638T1 (de) 3-arylindolderivate und deren verwendung als cb2- rezeptoragonisten
ATE496032T1 (de) 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE60107221D1 (de) Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE398108T1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
ATE306470T1 (de) Kondensierte indolinderivate und deren verwendung als 5ht, insbesondere 5ht2c, rezeptor liganden
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE50001729D1 (de) N-(indolcarbonyl-)piperazinderivate als 5-ht2a-rezeptor liganden
DE50105955D1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
DE60123458D1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
ATE252079T1 (de) Indolderivate und deren verwendung als 5ht2a liganden
ATE353881T1 (de) 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
DE60036885D1 (de) Succinimidverbindungen und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328515

Country of ref document: EP

REN Ceased due to non-payment of the annual fee